Karyopharm Therapeutics (KPTI) EBITDA Margin (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported EBITDA Margin of 93.03% for Q4 2025, up 19545.0% on a YoY basis from N/an in Q4 2024, and up 369.22% quarter-over-quarter from 34.56% in Q3 2025.
Karyopharm Therapeutics (KPTI) EBITDA Margin (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported EBITDA Margin for 14 years, with the latest figure at 93.03% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 19545.0% year-over-year to 93.03%; the trailing twelve-month figure through Dec 2025 stood at 28.18% (up 5406.0% YoY), and the FY2025 full-year result was 28.18%, up 5406.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 93.03%, up from 34.56% in the prior quarter.
- The five-year high for EBITDA Margin was 93.03% in Q4 2025, with the low at 225.16% in Q1 2021.
- Historically, EBITDA Margin has averaged 85.0% across 5 years, with a median of 86.07% in 2022.
- Annual changes were most pronounced in 2022 — EBITDA Margin plunged 13805 bps — and 2025, when it jumped 19545 bps.
- Karyopharm Therapeutics' EBITDA Margin stood at 37.19% in 2021, then plunged by 371 bps to 100.86% in 2022, then decreased by 11 bps to 112.03% in 2023, then rose by 9 bps to 102.42% in 2024, then jumped by 191 bps to 93.03% in 2025.
- The last three EBITDA Margin figures came in at 93.03% (Q4 2025), 34.56% (Q3 2025), and 64.3% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 93.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 93.03% |
| Sep 30, 2025 | -34.56% |
| Jun 30, 2025 | -64.30% |
| Mar 31, 2025 | -110.80% |
| Dec 31, 2024 | -102.42% |
| Sep 30, 2024 | -67.77% |
| Jun 30, 2024 | -65.72% |
| Mar 31, 2024 | -101.91% |
| Dec 31, 2023 | -112.03% |
| Sep 30, 2023 | -86.81% |
| Jun 30, 2023 | -78.70% |
| Mar 31, 2023 | -79.85% |
| Dec 31, 2022 | -100.86% |
| Sep 30, 2022 | -85.32% |
| Jun 30, 2022 | -108.14% |
| Mar 31, 2022 | -72.55% |
| Dec 31, 2021 | 37.19% |
| Sep 30, 2021 | -116.25% |
| Jun 30, 2021 | -217.02% |
| Mar 31, 2021 | -225.16% |